Moreover, Zhou et al. reported that CTCs can be classified into epithelial and mesenchymal CTCs, and that CRC patients with elevated levels of CD133-positive mesenchymal CTCs were more prone to distant metastases and exhibited poorer PFS [55]. The gene discussed is PROM1; the disease is colorectal carcinoma.